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latelet Reactivity in Patients
nd Recurrent Events Post-Stenting
esults of the PREPARE POST-STENTING Study
aul A. Gurbel, MD,* Kevin P. Bliden, BS,* Kirk Guyer, BS,† Peter W. Cho, MD,‡ Kazi A. Zaman, MD,*
olf P. Kreutz, MD,* Ashwani K. Bassi, MD,* Udaya S. Tantry, PHD*
altimore, Maryland; and South Bend, Indiana
OBJECTIVES We investigated the relation of high ex vivo platelet reactivity, rapid fibrin generation, and
high thrombin-induced clot strength to postdischarge ischemic events in patients undergoing
percutaneous coronary intervention (PCI).
BACKGROUND High platelet reactivity and rapid fibrin generation may affect the incidence of ischemic events
after PCI. However, limited data is available to link these ex vivo markers to the occurrence
of events.
METHODS We measured platelet reactivity to adenosine diphosphate (ADP) by light transmittance
aggregometry (LTA) in patients undergoing PCI (n  192). Clot strength, a measure of
thrombin-induced fibrin and platelet interactions, and the time to initial fibrin generation, a
marker of thrombin activity, were measured by thrombelastography. The relation of these
measurements to ischemic event occurrence was prospectively examined over six months.
RESULTS A total of 100% and 84% of patients were on aspirin and clopidogrel therapy, respectively, at
the time of the initial event. Posttreatment ADP-induced aggregation by LTA (63 12% vs.
56  15%, p  0.02) and clot strength (MA) were higher (74  5 mm vs. 65  4 mm,
p 0.001) and time to initial fibrin generation was shorter (4.3 1.3 min vs. 5.9 1.5 min,
p  0.001) in patients with events (n  38). The event rates in the highest quartiles of LTA
and MA were 32% and 58%, respectively.
CONCLUSIONS High platelet reactivity and clot strength, and rapid fibrin formation are novel risk factors for
ischemic events after PCI. Clot strength is more predictive than ADP-induced platelet
aggregation and may explain the occurrence of events despite treatment with
cyclooxygenase-1 and P2Y12 inhibitors. (J Am Coll Cardiol 2005;46:1820–6) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.041the American College of Cardiology Foundation
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flatelet aggregation and activation mediated by various
gonists play fundamental roles in the development of
schemia in patients with coronary artery diseases (1).
ctivated platelets mediate vessel wall inflammation, and
eneration of thrombin and platelet-platelet aggregates
echanically obstruct the vessel lumen (2). These funda-
ental properties served as the rationale for the evaluation
f dual antiplatelet therapy in two major clinical trials (3,4).
he Clopidogrel for the Reduction of Events During
bservation (CREDO) and Percutaneous Coronary
ntervention-Clopidogrel in Unstable angina to prevent
ecurrent ischemic Events (PCI-CURE) studies clearly
emonstrated the beneficial effects of dual antiplatelet ther-
py after percutaneous coronary intervention in patients
ith unstable coronary artery syndromes and provided
trong support for the clinical significance of platelet inhi-
ition. However, recurrent ischemic events occurred in 8.5%
o 8.8% of patients despite dual antiplatelet therapy (3,4).
From the *Sinai Center for Thrombosis Research, Baltimore, Maryland; †Indiana
niversity, Department of Chemistry, South Bend, Indiana; and the ‡Department of
urgery, Sinai Hospital, Baltimore, Maryland. This study was supported by National
nstitutes of Health (NIH) grant 5R44HL059753-03 and a grant from Haemoscope
orporation, Niles, Illinois.P
Manuscript received April 14, 2005; revised manuscript received July 8, 2005,
ccepted July 11, 2005.Because ischemic events are strongly influenced by
latelet-mediated events, it is logical to hypothesize that
atients suffering these events will have greater ex vivo
latelet reactivity than those without events despite the use
f antiplatelet drugs (5). A major reason for the lack of data
orrelating individual platelet function to the occurrence of
schemic events is the tedious nature, labor, and expense of
erial testing with conventional laboratory assays (6). Aden-
sine diphosphate (ADP), thromboxane A2, and thrombin
re important in vivo platelet agonists (1). Among patients
ndergoing percutaneous coronary intervention (PCI), pa-
ients with high platelet reactivity to low concentration
DP and lowest inhibition of ADP-induced platelet
ggregation had the greatest incidence of ischemic events
fter the procedure (7,8). In addition, the physical
roperties of the clot and the kinetics of thrombin-
ependent fibrin generation may affect the occurrence of
schemic events. We hypothesized that high ex vivo
latelet reactivity, rapid fibrin generation, and high
hrombin-induced clot strength (MA) as measured by the
hrombelastograph (TEG) Hemostasis Analyzer (Hae-
oscope Corporation, Niles, Illinois) were risk factors
or postdischarge ischemic events in patients undergoing
CI (9 –12).
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atients. The Investigational Review Board at Sinai Hos-
ital of Baltimore approved this study. Consecutive patients
ndergoing nonemergent coronary stenting provided in-
ormed consent before the procedure. Study inclusion re-
uired that patients had to undergo percutaneous revascu-
arization and be discharged from the hospital. Patients who
rovided informed consent but received coronary bypass
urgery for revascularization were excluded. All patients
ere 18 years old. Other exclusion criteria were a history
f bleeding diathesis, acute myocardial infarction within
8 h, elevated cardiac markers (above upper limits normal
or the respective assay), cerebrovascular event within 3
onths, chronic vessel occlusion or angiographically visible
hrombus, illicit drug or alcohol abuse, prothrombin time
reater than 1.5 control, platelet count 100,000/mm3,
ematocrit 30%, creatinine 4.0 mg/dl, and glycoprotein
GP) IIb/IIIa inhibitor use before the procedure.
A total of 135 patients received a loading dose of
lopidogrel (300 mg [n  75], 600 mg [n  60]) in the
atheterization laboratory immediately after successful
tenting. Patients on a maintenance dose of clopidogrel at
he time of admission (n  57) did not receive a loading
ose. A GP IIb/IIIa inhibitor (eptifibatide, n  92) was
dministered at the discretion of the treating physician.
atients not treated with GP IIb/IIIa inhibitors received
nfractionated heparin to achieve an activated clotting time
igure 1. Schematic of thrombelastograph system: a torsion wire suspend
5°, the pin will rotate depending on the strength of the fibrin-platelet bon
Abbreviations and Acronyms
ADP  adenosine diphosphate
GP  glycoprotein
LTA  light transmittance aggregometry
MA  clot strength
PCI  percutaneous coronary intervention
PPP  platelet-poor plasma
PRP  platelet-rich plasma
R  reaction time
ROC receiver operator curve
TEG  thrombelastograph
TVR  target vessel revascularizationime [R]) and the clot strength (MA).300 s, and patients treated with a GP IIb/IIIa inhibitor
chieved an activated clotting time of 200 s to 250 s. Aspirin
as administered at a 81- to 325-mg daily dose for seven
ays before the procedure, and 325 mg was administered on
he day of the procedure and daily thereafter. The mainte-
ance dose of clopidogrel was 75 mg daily.
lood sampling. Pretreatment blood samples were ob-
ained in the catheterization laboratory before GP IIb/IIIa
nhibitor or heparin administration through the indwelling
emoral vessel sheath and transferred to vacutainer blood
ollecting tubes (Becton-Dickinson, Franklin Lakes, New
ersey) containing 3.8% trisodium citrate (for light trans-
ittance aggregometry [LTA]) or 40 USP lithium heparin
for TEG assay) after discarding the first 2 to 3 ml of free
owing blood. The vacutainer tube was filled to capacity
nd gently inverted three to five times to ensure complete
ixing of the anticoagulant. Blood samples were obtained at
east 18 h after cessation of therapy in patients treated with
GP IIb/IIIa inhibitor. In the remaining patients, the
ischarge blood samples were obtained at least 24 h
ostprocedure.
TA. Platelet aggregation was assessed as described previ-
usly (13). Briefly, the blood-citrate tubes were centrifuged
t 120 g for 5 min to recover platelet-rich plasma (PRP) and
urther centrifuged at 850 g for 10 min to recover platelet-
oor plasma (PPP). The PRP and PPP were stored at room
emperature to be used within 2 h. Platelets were stimulated
ith 20 M ADP, and the aggregation was assessed using
Chronolog Lumi-Aggregometer (Model 490-4D) with
he Aggro/Link software package (Chronolog, Havertown,
ennsylvania). Aggregation was expressed as the maximum
ercent change in light transmittance from baseline, using
PP as a reference.
A and fibrin generation time. The TEG Hemostasis
nalyzer with automated analytical software provides quanti-
ative and qualitative measurements of the physical properties
f a clot (9–11). In essence, the TEG is a viscoelastic monitor
hat measures the degree of platelet-fibrin-mediated MA.
ibrin strands in the blood sample link a rotating sample cup
ith a stationary pin suspended by a torsion wire (Fig. 1). The
pin that is immersed in blood. As the clot forms while the cup is rotated
gnal is discharged continuously that reflects the onset of clotting (reactioning a
t
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Platelet Reactivity and Ischemic Events November 15, 2005:1820–6orque of the rotating cup is transmitted to the immersed pin.
in movement is converted to an electrical signal by a trans-
ucer and is interpreted by the computer to create a tracing.
he degree of platelet contribution to the MA through
latelet-fibrin bonding directly influences the magnitude of pin
Table 1. Patient Demographics
Patien
Ischem
(n 
Age (yrs) 59
Race (Caucasian) (%) 6
Gender (male) (%) 4
BMI (kg/m2) 31
Risk factors/past medical history (%)
Smoking 3
Family history of CAD 4
Hypertension 8
Hyperlipidemia 9
Diabetes 5
Prior myocardial infarction 2
Prior CABG 1
Prior PTCA 4
Pretreatment medications (%)
Beta-blockers 9
ACE inhibitors 7
Calcium-channel blockers 2
Lipid-lowering agents
3A4 pathway metabolized 7
Non-3A4 pathway metabolized 1
Laboratory data
WBC ( 1,000/mm3) 7.3
Platelets ( 1,000/mm3) 244
Hemoglobin (g/dl) 12.7
Creatinine (g/dl) 1.1
ACE  angiotensin-converting enzyme; BMI  body mas
coronary artery disease; PTCA  percutaneous coronary an
3A4.
Table 2. Procedural Characteristics
Patients W
Ischemic E
(n  3
Length of procedure (min) 55  2
Ejection fraction (%) 48  9
Number of vessels treated 1.3  0
Lesion morphology
De novo (%) 87
Culprit lesion location (%)
LAD 40
CX 21
RCA 34
SVG 5
Stent types (%)
Drug-eluting 75
Bare-metal 18
PTCA only 7
Reference vessel diameter (mm) 3.0  0
Total lesion length (mm) 21.9  1
Prestenosis (%) 86
Poststenosis (%) 5
Procedural success (%) 95CX circumflex artery; LAD left anterior descending artery; PT
 right coronary artery; SVG  saphenous vein graft.ovement and ultimately the amplitude of the tracing. In
he present study, the maximum amplitude of the
hrombin-generated clot (MA) (mm) and the time from
he start of the sample run to the first significant levels of
lot formation (reaction time [R]) (min) were measured (Fig.
ith
ents
Patients Without
Ischemic Events
(n  154)
p
Value
62  12 NS
57 NS
60 0.05
30  7 NS
45 NS
32 NS
63 0.04
57 0.001
40 NS
40 NS
26 NS
39 NS
81 NS
61 NS
22 NS
61 NS
24 NS
7.6  2.4 NS
222  66 NS
13.3  1.8 NS
1.1  0.8 NS
x; CABG  coronary artery bypass graft surgery; CAD 
ty; WBC  white blood cells; 3A4  hepatic cytochrome
Patients Without
Ischemic Events
(n  154)
p
Value
62  34 NS
52  9 NS
1.3  0.6 NS
89 NS
38 NS
25 NS
30 NS
7 NS
68 NS
29 NS
3 NS
3.0  0.5 NS
19.0  12.2 NS
84 NS
5 NS
96 NSts W
ic Ev
38)
 10
8
2
 7
9
7
1
2
0
4
8
2
0
4
1
4
8
 2.3
 79
 2.3
 0.6
s indeith
vents
8)
2
.5
.4
0.1CA percutaneous transluminal coronary angioplasty; RCA
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November 15, 2005:1820–6 Platelet Reactivity and Ischemic Events). The R parameter, a measure of initial thrombin-generated
brin formation, has been correlated with the velocity of
hrombin generation (9).
Blood was analyzed according to the manufacturer’s
nstructions; 1 ml of heparinized blood was transferred to a
ial containing kaolin and mixed by inversion; 500 l of the
ctivated blood was then transferred to a vial containing
eparinase and mixed to neutralize the heparin. The neu-
ralized blood (360 l) was immediately added to a
eparinase-coated cup and assayed in the TEG analyzer
ccording to the manufacturer’s instructions to obtain the
hrombin-induced clot.
efinitions and clinical outcomes. Patients were con-
acted by telephone at the end of one month and six months
o determine the occurrence of adverse events. Ischemic
vents were defined as the occurrence of death secondary to
ardiovascular cause, myocardial infarction, unstable angina,
nd stroke that required rehospitalization. Myocardial in-
arction was defined as the occurrence of ischemic symp-
oms and a troponin I value greater than upper limits of
ormal. Unstable angina was defined as the occurrence of
schemic symptoms requiring rehospitalization. A physician
linded to the study results of the patient diagnosed all end
oints. Patients were divided into two groups based on the
ccurrence of adverse ischemic events. High LTA and MA
ere defined as 75th percentile. Low R was defined as
25th percentile.
tatistical analysis. The linear logistic regression model
as employed to fit the binary data (ischemic event 1 and
onischemic event 0) while comparing different quartiles.
igure 2. Graph demonstrating the time of occurrence of the first ischemic
vent.
Table 3. Evaluation of Platelet Function Tests
Pati
Ische
20 M ADP-induced pretreatment
aggregation (%)
7
20 M ADP-induced post-treatment
aggregation (%)
6
TEG MA pretreatment (mm) 7
TEG MA post-treatment (mm) 7
Reaction time pretreatment (min) 4
Reaction time post-treatment (min) 4ADP  adenosine diphosphate; MA  clot strength; TEG  thrhis logistic regression model was fit using SAS procedure
ROC LOGISTIC (SAS Inc., Cary, North Carolina). The
odel is given by:
Logit(p)Logp ⁄ 1 p0  1 · QUARTILE_X
here p  proportion of incidence of ischemic event, and
UARTILE_X is a factor with four quartiles of the variable
as its four levels. Appropriate pairwise comparisons were
ade using the corresponding contrasts to assess the differ-
nce between the two levels of the factor with respect to the
roportion of ischemic events. The three variables (possible
) considered here are MA, LTA, and R.
The multiple linear logistic regression model was em-
loyed to fit binary data to compare the occurrence of
ifference risk factors in patients with ischemic events and
ithout ischemic events. The logistic regression model was
t using SAS procedure PROC LOGISTIC (SAS Inc.).
dds ratio were calculated using SAS software, and receiver
perator curves (ROC) were generated using MedCalc
oftware (Mariakerke, Belgium). Based on the normal
istribution of data, the mean  SD is reported except as
therwise noted, and p  0.05 was considered significant.
ESULTS
atients and clinical outcomes. A total of 192 patients
nderwent catheter-based treatment and were analyzed. All
f the procedures performed were nonemergent; 36 patients
igure 3. Adenosine-diphosphate-induced posttreatment platelet aggrega-
ion (20 M) measured by light transmittance aggregometry (LTA) in
atients without ischemic events and with ischemic events.
ight Transmittance Aggregometry and TEG
With
vents
Patients Without
Ischemic Events
p
Value
73  12 NS
2 56  16 0.02
67  8 0.001
65  4 0.001
.3 4.7  2.0 NS
.3 5.9  1.5 0.001by L
ents
mic E
1  9
3  1
2  7
4  5
.6  2
.3  1ombelastograph.
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Platelet Reactivity and Ischemic Events November 15, 2005:1820–6ere admitted with unstable angina, and 11 patients had
on–ST-segment elevation myocardial infarction. The re-
ainder of the patients had stable angina. The patient
emographics and procedural characteristics of patients
ith and without ischemic events are shown in Tables 1 and
, respectively. There were four in-hospital ischemic events.
ll of these patients had myocardial infarction diagnosed by
he occurrence of chest pain and increase in troponin I
reater than upper limits normal. One of these patients had
tent thrombosis.
Six-month follow-up data were complete in 191 of 192
atients. There were 44 events that occurred in 38 patients
20%) within six months of discharge (Fig. 2). All events
ccurred during aspirin therapy. Thirty-two patients were
eceiving aspirin and clopidogrel therapy at the time of their
rst event. Within one month after discharge, 20 of 191
atients (10%) had events: myocardial infarction involving
arget vessel (n  2), ischemia requiring revascularization of
he prior target vessel (TVR) (n  2 patients), ischemia
nvolving a vessel other than the prior target vessel requiring
evascularization (non-TVR) (n  6), ischemia requiring
ospitalization but not revascularization (n  9), and stroke
n  1). Between one and six months, 18 patients had the
rst occurrence of an event: death (n  2), ischemia
igure 4. The observed frequency of patients with ischemic events in each
uartile of light transmittance aggregometry (LTA) values is shown in the
gure. The p values given in the figure indicate that the proportions of
schemic events in the first and the fourth quartiles are significantly
ifferent, whereas the proportions of ischemic events in the fourth quartile
re not significantly different from the second or the third quartiles.igure 5. Post-treatment clot strength (MA) measured by thrombelasto-
raph (TEG) in patients without ischemic events and with ischemic events.
t
eequiring TVR (n  6), ischemia requiring non-TVR (n 
), and ischemia requiring hospitalization but not revascu-
arization (n  6). Six patients had the occurrence of a
econd event between one and six months: coronary artery
ypass grafting (n  2), ischemia requiring TVR (n  1),
schemia requiring non-TVR (n  1), and ischemia requir-
ng hospitalization but not revascularization (n  2).
latelet aggregation. A total of 160 patients had platelet
ggregation measured by LTA, and 192 patients had blood
amples analyzed by the TEG system (Table 3). Pretreat-
ent aggregation by LTA was 71  9% in patients with
schemic events and 73  12% in patients without ischemic
vents (p  NS). Patients with ischemic events demon-
trated a higher mean discharge ADP-induced platelet
ggregation by LTA than patients without ischemic events
p  0.02) (Table 3, Fig. 3). The change in mean platelet
ggregation between pre- and postprocedure for the event
roup was 8% versus 17% for the group without events (p
.001). The greatest frequency of patients with ischemic
vents was present in the highest quartile of platelet aggre-
ation (Fig. 4).
A and R by TEG. Patients with ischemic events had
ignificantly greater pre- and posttreatment MA than pa-
ients without ischemic events (p 0.001) (Table 3, Fig. 5).
igure 6. Post-treatment reaction time measured by thrombelastograph in
atients without ischemic events and with ischemic events.
igure 7. The observed frequency of patients with ischemic events in each
uartile of clot strength (MA) values is shown in the figure. The p values
iven indicate that the proportion of ischemic events in each of the first
hree quartiles is significantly different from the proportion of ischemic
vents in the fourth quartile (p  0.001). TEG  thrombelastograph.
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November 15, 2005:1820–6 Platelet Reactivity and Ischemic Eventshe R did not differ between groups at baseline but was
ignificantly shorter in patients with events when measured
ostprocedure (p  0.001) (Fig. 6). The highest quartile of
A and the lowest quartile of thrombin generation time
ere associated with the maximum occurrence of ischemic
vents (Figs. 7 and 8, respectively).
atients with ischemic events. The occurrence of risk
actors (high MA, low R, and high LTA) in patients with
nd without ischemic events, estimates of the parameters of
he logistic regression model, odds ratios, and 95% confi-
ence intervals are presented in Table 4. Among the 38
atients with events, only 4 patients had no risk factors at all
11%) as compared to 56% in the nonischemic group (p 
.0001). The most prevalent risk factor in patients with
schemia was high MA (71%) with odds ratio estimate of
2.6 (95% confidence interval, 6.20 to 82.60), followed by a
ow R (42%, p  0.05) with odds ratio estimate of 4.4 (95%
onfidence interval 1.00 to 19.05) and high LTA (35%, p
.21) with odds ratio estimate of 2.7 (95% confidence
nterval 0.56 to 12.96). Only 12% of patients without events
emonstrated a high MA (p  0.0001). The combined
resence of two major risk factors, high MA and low R, in
he ischemic events group was significantly higher (29%)
ompared to the non-ischemic events group (4%, p 
.0001). The presence of all three risk factors was 100%
redictive of an ischemic event.
igure 8. The observed frequency of patients with ischemic events in each
uartile of reaction time (R) values is shown in the figure. The p values
ndicate that the proportions of ischemic events in first and the second
uartiles are not significantly different (p  0.41) whereas the proportions
f ischemic events in the first quartile is significantly different from the
hird (p  0.006) and the fourth quartiles (p  0.004). TEG 
hrombelastograph.
able 4. Observed Frequency (%) of Patients Without Ischemic E
f the Parameters of the Logistic Regression Model, Odds Ratio,
High MA Lo
atients without ischemic events, n (%) 18 (12%) 31
atients with ischemic events, n (%) 27 (71%) 16
stimate (SE) 3.12 (0.66) 1.47
Value 0.0001 0.0
dds ratio estimate 22.6 4
5% confidence interval for the odds ratio 6.202–82.604 1.002TA  light transmittance aggregometry; MA  clot strength; R  reaction time.The combined ROC, sensitivity, and specificity for risk
actors are shown in Figure 9. A high MA was the most
pecific and sensitive risk factor for the occurrence of
schemic events.
ISCUSSION
he current study suggests that in addition to high ex vivo
latelet reactivity to ADP, greater overall MA and rapid
brin generation are novel risk factors for the occurrence of
ost-PCI ischemic events. Greater reactivity to ADP in
atients with ischemic events was supported by conven-
ional LTA, the most common measurement reported in
he literature. Thrombelastograpy has never been used as a
redictive tool for ischemic events after PCI but has
redictive value in surgical patients as a method to deter-
ine etiologies of bleeding (9,10). In the only other study
hat evaluated MA as a risk factor for thrombosis, McCrath
t al. (11) demonstrated that noncardiac surgical patients
ith ischemic events had a significantly higher MA than
hose without events (73 vs. 65 mm, respectively).
hese data are concordant with our study.
A low incidence of ischemic events was observed in
atients within the lowest quartile of aggregation measured
igure 9. Combined receiver operator curve for clot strength (Thrombelas-
ograph [TEG] MA), reaction time (TEG R), and 20 M adenosine-
iphosphate-induced posttreatment platelet aggregation (light transmit-
ance aggregometry [LTA]). High TEG MA has 74% sensitivity and 89%
pecificity; low TEG R has 42% sensitivity and 79% specificity; high LTA
as 37% sensitivity and 79% specificity.
ts and With Ischemic Events in Risk Factor Groups, Estimates
95% Confidence Intervals for the Odds Ratio
High LTA High MA and Low R
No Risk
Factor
) 30 (20%) 6 (4%) 83 (56%)
) 13 (35%) 11 (29%) 4 (11%)
) 0.99 (0.80) 3.64 (0.72) —
0.2129 0.0001 —
2.7 38.0 —
51 0.565–12.964 9.261–156.245 —ven
and
w R
(21%
(42%
(0.75
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.4
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Platelet Reactivity and Ischemic Events November 15, 2005:1820–6y LTA, indicating the influence of successful P2Y12
eceptor blockade in the prevention of ischemic events.
ndeed, the decrease in ADP-induced platelet aggregation
evels after antiplatelet therapy was less pronounced in
atients with events as compared to patients without events.
he change in mean platelet aggregation between pre- and
ostprocedure for the event group was 8% versus 17% for
he group without events (p  0.001). The near absence of
vents in patients with 50% posttreatment aggregation
nduced by 20 M ADP may also suggests a therapeutic
arget for P2Y12 inhibitors. More importantly,50% of the
vents occurred in patients with 25th to 75th percentile
osttreatment platelet reactivity to ADP. This observation
trongly suggests that agonists other than ADP play a domi-
ant role in the genesis of ischemic events and that antiplatelet
herapy directed against P2Y12 and cyclooxygenase-1 in the
urrent dosages is not sufficient to overcome thrombosis in
elected patients.
In the current investigation, maximum MA measured by
he TEG analyzer was the most sensitive and specific
arker of ischemic risk and supports the central role of
latelet reactivity to thrombin in recurrent ischemia post-
CI. A total of 58% of patients in the highest MA quartile
eveloped events whereas those in the lowest two quartiles
lower quartiles) were nearly free of events. A total of 71%
f the patients suffering from events were classified in the
ighest quartile of MA, and only 12% of patients without
vents were ranked in the highest quartile. Of these 12%,
6% had normal R as measured by the TEG analyzer. In
40% of cases where the MA was high (75th percentile),
nd an event occurred, the R was low (25th percentile).
hen high MA was accompanied by a low R, there was an
xtremely high occurrence of ischemic events (odds ratio
8.0, p  0.0001). These findings suggest that rapid
hrombin generation often accompanies high MA. All of
ur data indicate that high responsiveness to thrombin (high
A) and accelerated thrombin generation (low R) are
mportant predictive ex vivo measurements. Thus, selected
atients with average ADP-induced posttreatment aggrega-
ion but with high MA and/or low R remain at risk for
vents.
Finally, the R significantly increased after PCI in those
atients without ischemic events whereas in patients with
vents the mean value decreased. These findings suggest
hat effective clopidogrel therapy may influence thrombin
eneration. It has been reported that clopidogrel reduces
hrombin generation (14,15).
tudy limitations. Patients were not stratified before clin-
cal events to different degrees of platelet reactivity or MA.
t is uncertain whether improvements in the degree of
latelet reactivity or MA before and after the procedure
ould help an individual patient in reducing their risk of a
uture ischemic event.
onclusions. High ex vivo platelet reactivity and rapid
eneration of fibrin are risk factors for the development of
schemic events within six months of PCI. Moreover, MA,marker of thrombin-induced platelet-fibrin aggregation, is
ore predictive than platelet reactivity to ADP. These
ndings may explain the occurrence of events despite
reatment with cyclooxygenase-1 and P2Y12 inhibitors.
urthermore, it suggests the need to address effective
nhibition of thrombin during and after PCI. Larger scale
linical trials are warranted to evaluate these prognostic
easures and their implementation for therapeutic
ecisions.
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